BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22231582)

  • 1. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.
    Herrmann K; Benz MR; Krause BJ; Pomykala KL; Buck AK; Czernin J
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):620-32. PubMed ID: 22231582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
    Chen Z; Li X; Li F; Ouyang Q; Yu T
    Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of PET/CT to evaluate response to therapy in lymphoma.
    Zanoni L; Cerci JJ; Fanti S
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):633-47. PubMed ID: 22231583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring cancer treatment with PET/CT: does it make a difference?
    Weber WA; Figlin R
    J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of therapy response in oncology.
    Chiti A; Oyen WJ
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):587-8. PubMed ID: 22231579
    [No Abstract]   [Full Text] [Related]  

  • 8. PET and PET/CT in pediatric oncology.
    Jadvar H; Connolly LP; Fahey FH; Shulkin BL
    Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H; Fury M; Lee N; Kraus D
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT.
    Hanrahan CJ; Christensen CR; Crim JR
    Radiographics; 2010 Jan; 30(1):127-42. PubMed ID: 20083590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
    Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
    J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future?
    Basu S; Rao R
    J Nucl Med; 2010 Jan; 51(1):165; author reply 166-7. PubMed ID: 20008984
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]FDG-PET-CT for early monitoring of tumor response: when and why.
    Storto G; Nicolai E; Salvatore M
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):167-80. PubMed ID: 19293765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.